XTalks

DECEMBER 18, 2024

The therapy is approved to be used in combination with glucocorticoid replacement therapies (steroids) to control androgen levels in adults and pediatric patients four years of age and older with classic CAH. Currently, the standard treatment for CAH involves glucocorticoids, which replace cortisol and help regulate hormone levels.

Genetics 116

Genetics Hormones Trials Drugs 116

XTalks

JANUARY 29, 2025

Related: Eli Lillys Zepbound Approved as First Treatment for Obstructive Sleep Apnea The commercial describes Zepbounds mechanism of action as a dual receptor against that works by activating two naturally occurring hormone receptors in [the] body [GLP-1 and GIP-1]. Its changing how much weight I lose, up to 48 lbs, he says.

FDA Approval 71

FDA Approval Drugs Hormones Marketing 71

XTalks

JULY 19, 2024

Compounded GLP-1 medications, created by specialized pharmacies under a special US Food and Drug Administration (FDA) allowance due to ongoing shortage, have become increasingly popular for weight loss. The report also shows a rapid rise in compounding pharmacies.

Pharmacy 104

Pharmacy Drugs Production Sales 104

XTalks

JUNE 5, 2023

Semaglutide acts as a glucagon-like peptide-1 (GLP-1) receptor agonist, mimicking the GLP-1 hormone released in the gastrointestinal tract after eating. mg and 1 mg doses will be available to wholesalers for distribution to retail pharmacies. Despite this, Novo Nordisk doesn’t anticipate interruptions in supplying 1.7 mg and 2.4

FDA Approval 98

FDA Approval Containment Drugs Pharmacy 98

XTalks

SEPTEMBER 13, 2024

Early this year, Elevance closed its acquisition of Paragon Healthcare, enhancing its specialty pharmacy and infusion services capabilities. Billion Cigna continues to innovate by expanding access to healthcare through its diverse portfolio of insurance, pharmacy benefits management and health services. billion in revenue.

Marketing 98

Marketing Pharmacy Gene Therapy Hormones 98

pharmaphorum

APRIL 1, 2022

And already in the first quarter of 2022, the FDA approved a third filgrastim biosimilar, Releuko. With 34 approved biosimilars and dozens more in the pipeline, what does this year have in store? In September of 2021, the FDA approved Byooviz , which references Roche and Novartis’ blockbuster eye drug Lucentis.

Marketing 59

Marketing Pharmacy FDA Approval Manufacturing 59

XTalks

MARCH 8, 2024

The biosimilar injections, Jubbonti (denosumab-bddz) and Wyost (denosumab-bddz), are approved as interchangeable biosimilars to Prolia and Xgeva, respectively. This means they can be substituted for the reference product at a pharmacy without the need for instruction from a prescriber.

Drugs 59

Drugs FDA Approval Production Immune Response 59